Literature DB >> 3858973

Development of an oral formulation of omeprazole.

A Pilbrant, C Cederberg.   

Abstract

Omeprazole has a low water solubility and is chemically labile in an acid environment. In the formulation of an oral dosage form of omeprazole the possibilities of dissolution rate limited absorption and preabsorption degradation must be kept in mind. A water suspension of omeprazole was tested in a pilot bioavailability study. The suspension was given to six healthy, fasting volunteers on two occasions--together with sodium bicarbonate solution and together with the same volume of water. When the suspension was given with water the bioavailability was reduced by about 50% owing to preabsorption degradation. In another bioavailability study the slowest of three granule formulations with differing in vitro dissolution rates showed a reduced extent of absorption. A controlled-release pellet formulation (enteric-coated) was formulated and tested in a series of bioavailability studies. A single dose given with food resulted in a delayed absorption and possibly lower bioavailability than under fasting conditions. When the granules were given on an empty stomach before the morning meal the length of time between dosage and meal was of no importance. Concomitant administration of a liquid antacid had no influence on the bioavailability of omeprazole.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3858973     DOI: 10.3109/00365528509095824

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  19 in total

1.  Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.

Authors:  M S Ching; G W Mihaly; P W Angus; D J Morgan; S Devenish-Meares; N D Yeomans; R A Smallwood
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration.

Authors:  Takenori Niioka; Tsukasa Uno; Katsuyoshi Sugimoto; Kazunobu Sugawara; Makoto Hayakari; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2007-08-16       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Solid-state interactions at the core-coat interface: physicochemical characterization of enteric-coated omeprazole pellets without a protective sub-coat.

Authors:  Vishnu Dutt Sharma; Suleyman Akocak; Marc A Ilies; Reza Fassihi
Journal:  AAPS PharmSciTech       Date:  2015-01-17       Impact factor: 3.246

5.  Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules.

Authors:  H A Tuynman; H P Festen; K Röhss; S G Meuwissen
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

6.  In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration.

Authors:  Ping Ren; Minglei Cui; Om Anand; Li Xia; Zhuojun J Zhao; Dajun Sun; Trueman Sharp; Dale P Conner; John Peters; Wenlei Jiang; Ethan Stier; Xiaojian Jiang
Journal:  AAPS J       Date:  2017-09-06       Impact factor: 4.009

7.  Pharmacokinetics of paracetamol in Göttingen minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption.

Authors:  Claudia Suenderhauf; Gerald Tuffin; Helle Lorentsen; Hans-Peter Grimm; Christophe Flament; Neil Parrott
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

Review 8.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 9.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

Review 10.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.